Psoriasis guide: the immune mechanism, triggers, and full treatment spectrum

Psoriasis is a chronic immune-mediated inflammatory disease affecting approximately 2–3% of the global population. It is not a cosmetic condition or a hygiene problem — it is driven by a well-characterized T-cell dysregulation involving the IL-17/IL-23 and TNF-α cytokine axes, and it carries systemic disease associations (psoriatic arthritis, cardiovascular disease, metabolic syndrome) that extend well beyond the skin. Here is the complete evidence-based guide.

Pathophysiology: the IL-17/IL-23 axis

The immune cascade

Psoriasis is driven by a dysregulated innate and adaptive immune response centered on the Th17 pathway:

Trigger events (infection, stress, trauma) activate dendritic cells in the skin → dendritic cells release IL-12 and IL-23
IL-23 drives differentiation and expansion of Th17 T cells (and Th1 cells via IL-12)
Th17 cells produce IL-17A, IL-17F, IL-22, and TNF-α
IL-17 acts on keratinocytes → dramatic upregulation of:
- Keratinocyte proliferation (accelerated from normal 28-day turnover to 3–4 days)
- Pro-inflammatory cytokine production (IL-6, IL-8, CXCL1)
- Chemokine release that recruits neutrophils → Munro's microabscesses (subcorneal neutrophil collections — pathognomonic histologic finding)
IL-22 drives epidermal hyperplasia (acanthosis) — the thick, raised psoriatic plaques
TNF-α amplifies the entire inflammatory cascade and promotes angiogenesis (the dilated tortuous capillaries visible through the thinned suprapapillary epidermis → the Auspitz sign when scales are removed)

The result: Hyperproliferating epidermis that cannot mature normally → parakeratotic cells (nucleated cells in the stratum corneum, which is normally anucleate) → the silvery-white scale (parakeratotic cells reflecting light) over an erythematous plaque (dilated vessels beneath the thin suprapapillary plate).

The keratinocyte feedback loop

Activated keratinocytes are not passive targets — they actively amplify the immune response:

Produce TSLP, IL-1β, and LL-37 → re-activate dendritic cells → sustain the IL-23→Th17 loop
The feedback makes psoriasis self-sustaining once established

Clinical subtypes

Plaque psoriasis (psoriasis vulgaris)

The most common form (85–90% of cases). Sharply demarcated, erythematous plaques with silvery-white scale. Typical sites: scalp, extensor surfaces (elbows, knees), lumbosacral region, umbilicus, intergluteal cleft. Nails affected in ~50% of plaque psoriasis patients.

Guttate psoriasis

Small (0.5–2 cm), raindrop-shaped papules erupting acutely across the trunk and limbs. Typically triggered by Group A Streptococcus pharyngitis (streptococcal superantigen activates T cells → rapid Th17 activation). Most common in children and young adults; often resolves spontaneously in weeks-months; may evolve into plaque psoriasis.

Pustular psoriasis

Sterile pustules on erythematous base. Two main forms:

Generalized (von Zumbusch): Acute, potentially life-threatening; widespread pustules, fever, systemic illness; requires emergency treatment
Palmoplantar pustulosis (PPP): Chronic pustules on palms and soles; debilitating; association with smoking

Inverse psoriasis

Affects skin folds (axillae, inguinal folds, inframammary areas, intergluteal cleft) — lacks the typical scale (moisture in folds dissolves scale); presents as smooth, bright red plaques; often confused with candidiasis or intertrigo.

Erythrodermic psoriasis

Generalized erythema and scaling covering >90% of body surface area; a medical emergency — thermoregulation failure, fluid loss, high-output cardiac failure risk.

Koebner phenomenon

Psoriatic lesions develop at sites of skin trauma (scratching, surgery, sunburn, injection sites) — the Koebner phenomenon (isomorphic response). Present in approximately 25–50% of psoriasis patients. Clinically important: avoiding skin trauma reduces new lesion development; tattoos and piercings can trigger Koebner responses.

Disease severity assessment

PASI (Psoriasis Area and Severity Index): The standard clinical measurement tool. Scores each body region (head, trunk, upper limbs, lower limbs) for erythema (redness), induration (thickness), desquamation (scaling), and percentage body surface area affected. Total score 0–72.

PASI <10: Mild
PASI 10–20: Moderate
PASI >20: Severe

PASI 75, PASI 90, PASI 100: Clinical trial response benchmarks — the percentage of patients achieving 75%, 90%, or 100% reduction from baseline PASI. Biologic trials now routinely report PASI 90 as the primary endpoint.

Treatment ladder

Topical therapy (mild-to-moderate, or adjunct to systemic)

Topical corticosteroids (TCS): First-line for most patients. High-potency (clobetasol, halobetasol) for thick plaques on body; medium-potency for sensitive areas and maintenance. The superpotent corticosteroid foam formulations (Olux-E, Luxíq) are particularly effective for scalp psoriasis.

Vitamin D analogues (calcipotriol/calcipotriene, calcitriol): Reduce keratinocyte proliferation and normalize differentiation via vitamin D receptor (VDR) activation. Effective as monotherapy for mild disease; highly synergistic with TCS (combination calcipotriol/betamethasone dipropionate — Taclonex, Enstilar — is the most effective topical agent for plaque psoriasis in controlled trials).

Tazarotene: A retinoid specifically FDA-approved for psoriasis; normalizes keratinocyte differentiation; used with TCS (the combination reduces tazarotene irritation while providing additive efficacy).

Topical calcineurin inhibitors: For inverse and facial psoriasis where TCS atrophy risk is prohibitive.

Tapinarof (Vtama) 1% cream: Novel aryl hydrocarbon receptor (AhR) agonist — FDA-approved 2022 for plaque psoriasis; steroid-free; works by downregulating IL-17A and IL-22 directly in keratinocytes.

Roflumilast (Zoryve) 0.3% cream: PDE4 inhibitor FDA-approved 2022 for plaque psoriasis.

Phototherapy (moderate-to-severe)

Narrowband UVB (NB-UVB, 311–313 nm): The most commonly used phototherapy; induces T-cell apoptosis and reduces Th17 cytokines in the skin; 3x/week for 12–16 weeks; effective for guttate and plaque psoriasis; safe in pregnancy; first-line for moderate-to-severe disease when systemic therapy is not yet needed.

PUVA (psoralen + UVA): More effective than NB-UVB but significantly more phototoxicity and long-term skin cancer risk; reserved for NB-UVB failures.

Systemic therapy (moderate-to-severe)

Methotrexate: Anti-folate immunosuppressant; the historical systemic workhorse for psoriasis; effective and inexpensive; requires liver monitoring (hepatotoxicity risk, especially with alcohol use).

Cyclosporine: Calcineurin inhibitor (systemic); rapid onset — useful for rapid control of severe flares; limited to short-term use (nephrotoxicity, hypertension with prolonged use).

Acitretin: Oral retinoid; particularly effective for pustular and erythrodermic psoriasis; teratogenic (requires contraception for 3 years after stopping in women of childbearing age).

Apremilast (Otezla): Oral PDE4 inhibitor; modest efficacy but excellent safety profile; no laboratory monitoring required; appropriate for patients who cannot use biologics.

Biologics (moderate-to-severe)

The transformative advance in psoriasis treatment — targeting the specific cytokines driving disease.

TNF-α inhibitors (adalimumab, etanercept, infliximab): First-generation biologics; effective (PASI 75 in ~60–70% of patients); now second-line to IL-17 and IL-23 inhibitors for skin disease.

IL-17 inhibitors (secukinumab, ixekizumab, bimekizumab): Target IL-17A (or IL-17A+F for bimekizumab) — the most directly pathogenic cytokine in skin psoriasis. Secukinumab ERASURE trial (Langley et al. 2014, NEJM): PASI 90 in 59% vs. 1% placebo — established IL-17 inhibition as the reference standard for psoriasis biologic efficacy.

IL-23 inhibitors (guselkumab, risankizumab, tildrakizumab): Target the p19 subunit of IL-23 — upstream of IL-17; high efficacy with less frequent dosing (every 8–12 weeks maintenance); PASI 90 rates of 70–80% in pivotal trials; rising to first-line position.

Psoriatic arthritis (PsA)

Approximately 25–30% of psoriasis patients develop psoriatic arthritis — an inflammatory arthropathy that can cause irreversible joint damage. It may precede, coincide with, or follow skin disease onset.

Screening: Any psoriasis patient with joint pain, morning stiffness, or nail changes should be assessed for PsA (PEST or PSIARC screening tools). Early biologic intervention prevents joint damage.

Treatment convergence: IL-17 inhibitors, IL-23 inhibitors, and TNF-α inhibitors are all effective for both skin and joint disease — making biologic selection more straightforward when both components are active.

Cardiovascular and metabolic comorbidities

Psoriasis is an independent cardiovascular risk factor — beyond what would be expected from shared lifestyle factors:

Higher rates of hypertension, dyslipidemia, diabetes mellitus, and obesity
Elevated CRP and inflammatory markers drive accelerated atherosclerosis
Patients with severe psoriasis have approximately 1.5× increased risk of major adverse cardiovascular events vs. matched controls

Clinical implication: Psoriasis patients should receive cardiovascular risk factor screening (blood pressure, lipids, glucose, BMI) as part of their dermatologic care.

Looking for a skincare or dermatology consultation? Browse med spa providers on MedSpot →